JPH0199609A - Reformed regenerated cellulose membrane and production thereof - Google Patents
Reformed regenerated cellulose membrane and production thereofInfo
- Publication number
- JPH0199609A JPH0199609A JP62253724A JP25372487A JPH0199609A JP H0199609 A JPH0199609 A JP H0199609A JP 62253724 A JP62253724 A JP 62253724A JP 25372487 A JP25372487 A JP 25372487A JP H0199609 A JPH0199609 A JP H0199609A
- Authority
- JP
- Japan
- Prior art keywords
- membrane
- regenerated cellulose
- acid
- blood
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 90
- 239000004627 regenerated cellulose Substances 0.000 title claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 22
- 238000005886 esterification reaction Methods 0.000 claims abstract description 20
- 230000032050 esterification Effects 0.000 claims abstract description 14
- 239000003054 catalyst Substances 0.000 claims abstract description 12
- 239000012429 reaction media Substances 0.000 claims abstract description 9
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 17
- -1 aliphatic carboxylic anhydride Chemical class 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 238000000034 method Methods 0.000 abstract description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 14
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 abstract description 12
- 229920005597 polymer membrane Polymers 0.000 abstract description 10
- 150000002148 esters Chemical class 0.000 abstract description 6
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 abstract description 5
- PKHMTIRCAFTBDS-UHFFFAOYSA-N hexanoyl hexanoate Chemical compound CCCCCC(=O)OC(=O)CCCCC PKHMTIRCAFTBDS-UHFFFAOYSA-N 0.000 abstract description 5
- 238000007654 immersion Methods 0.000 abstract description 3
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 abstract 1
- 230000002542 deteriorative effect Effects 0.000 abstract 1
- 239000011877 solvent mixture Substances 0.000 abstract 1
- 239000012510 hollow fiber Substances 0.000 description 27
- 238000000502 dialysis Methods 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 102000000989 Complement System Proteins Human genes 0.000 description 3
- 108010069112 Complement System Proteins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- ZURAKLKIKYCUJU-UHFFFAOYSA-N copper;azane Chemical compound N.[Cu+2] ZURAKLKIKYCUJU-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000004388 gamma ray sterilization Methods 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- ISYWECDDZWTKFF-UHFFFAOYSA-N nonadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(O)=O ISYWECDDZWTKFF-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000005643 Pelargonic acid Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- KJDZDTDNIULJBE-QXMHVHEDSA-N cetoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCCCC(O)=O KJDZDTDNIULJBE-QXMHVHEDSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- ZTGSNOLGYUVZDM-UHFFFAOYSA-N propan-2-one;1,1,2-trichloro-1,2,2-trifluoroethane Chemical compound CC(C)=O.FC(F)(Cl)C(F)(Cl)Cl ZTGSNOLGYUVZDM-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Materials For Medical Uses (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Artificial Filaments (AREA)
Abstract
Description
ãçºæã®è©³çŽ°ãªèª¬æã
ãç£æ¥äžã®å©çšåéã
æ¬çºæã¯ã人工èåšçã«çšããããæ¹è³ªãããåçã»ã«
ããŒã¹èåã³ãã®è£œé æ³ã«é¢ãããæŽã«è©³ããã¯ãè¡æ¶²
ã«å¯Ÿããé©åæ§ãæ¹è³ªãããåçã»ã«ããŒã¹èåã³ãã®
補é æ³ã«é¢ãããDETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a modified regenerated cellulose membrane used for artificial organs, etc., and a method for producing the same. More specifically, the present invention relates to a regenerated cellulose membrane with improved blood compatibility and a method for producing the same.
è¿å¹Žã人工è
èã人工èºãè¡æŒ¿åé¢è£
眮çã®èãçšãã
人工èåšããé·æ©ã®çºå±ãéããŠããŠãããåšç¥ã®ãã
ã«ãç¹ã«äººå·¥éæçæ³ã«æŒããŠãåçã»ã«ããŒã¹èããš
ãããé
ã¢ã³ã¢ããŠã æ³åçã»ã«ããŒã¹èã¯ãåºãçšã
ãããéæè£
眮ãéææè¡ã®é²æ©ãšå
±ã«ãè
äžå
šæ£è
ã®
延åœã瀟äŒåŸ©åž°ã«å€§ããªåœ¹å²ãæãããŠãããããã¯ã
åçã»ã«ããŒã¹èãåªããéææ§èœãæ©æ¢°ç匷床ãæã
ããšãšãã«ãé·å¹Žã®å®çžŸã«è£ä»ãããé«ãå®å
šæ§ãæã
ãŠããããã«ä»ãªããªããIn recent years, artificial organs using membranes, such as artificial kidneys, artificial lungs, and plasma separation devices, have made great progress. As is well known, especially in artificial dialysis therapy, regenerated cellulose membranes, especially copper ammonium regenerated cellulose membranes, are widely used, and along with advances in dialysis equipment and dialysis technology, they play a major role in prolonging the lives of renal failure patients and reintegrating them into society. is fulfilled. this is,
This is because regenerated cellulose membranes have excellent dialysis performance and mechanical strength, as well as high safety backed by many years of experience.
ããããªãããéæçæ³ã®é²æ©ã«ãããããããéæã«
䌎ãçš®ã
ã®åé¡ããŸã æªè§£æ±ºã§æ®ãããŠãããäŸãã°ã
æååºå€ãé·æ倧éæäžããããã®ããã«çãããšèã
ãããçš®ã
ã®å¯äœçšã®åé¡ããŸããåçã»ã«å·šâã¹èã
ãã®ä»äžéšã®èã§è¡æ¶²éæãè¡ã£ãå Žåã®äžéæ§ã®çœè¡
çæžå°ãè£äœæåã®æŽ»æ§åã®åé¡çãææãããŠãããHowever, despite advances in dialysis therapy, various problems associated with dialysis still remain unsolved. for example,
There are concerns about the various side effects that may occur due to long-term administration of large doses of anticoagulants, as well as the temporary decrease in white blood cells caused by hemodialysis using regenerated cell giant membranes and some other membranes. Problems with activation of complement components have been pointed out.
åŸè
ã®çŸè±¡ã«ã€ããŠã¯ãèšåºçç¶ãšã®é¢é£ãæãã¯èšåº
çæ矩ã¯æããã§ã¯ãªãããåçã»ã«ããŒã¹èã®ä»ã®åª
ããæ§èœãæãªããããããã®çŸè±¡ã軜æžããããšãæ
ãŸããŠãããRegarding the latter phenomenon, although the relationship with clinical symptoms or clinical significance is not clear, it is desired to alleviate these phenomena without impairing the other excellent performance of the regenerated cellulose membrane.
ãããåé¡ãçŸè±¡ã«å¯ŸããŠãåæé«ååãããªãèãã
æ¯èŒç軜埮ãªé¢ããããšææ¡ãããŠãããããããã®è
ã§ã¯æ©æ¢°ç匷床ã匱ããã³ããŒã«ãçºçãæãããšãè
ç±æ§ãå
åã§ãªãããæ»
èæ³ãéå®ãããããšãåã³æ§
èœã®ãã©ã³ã¹ãå³ã¡éæ°Žéãšç©è³ªéééã®ãã©ã³ã¹ãæª
ããã®äœ¿çšæ¹æ³ãç¹å®ããããšãã£ãæ¬ ç¹ããããTo solve these problems and phenomena, membranes made of synthetic polymers can
Although it has been proposed that these membranes have relatively minor aspects, the mechanical strength of these membranes is weak and pinholes are likely to occur, the sterilization method is limited due to insufficient heat resistance, and the balance of performance, That is, there is a drawback that the balance between the amount of water permeated and the amount of material permeated is poor, making it difficult to specify how to use it.
äžæ¹ãåçã»ã«ããŒã¹èã®è¡æ¶²èŠªåæ§ãæ¹è³ªããæ¹æ³ã
çš®ã
ææ¡ãããŠãããäŸãã°ãèè¡šé¢ããããªã³åãã
ããšã«ããæè¡æ æ§ãä»äžããæ¹æ³ãæéïŒïŒâïŒïŒïŒ
å·å
¬å ±ã§ææ¡ãããŠããããå
åãªå¹æãåŸãããããŸ
ãã³ã¹ããå²é«ã«ãªãããå®çšåãããŠããªãããŸãã
åçš®ããªããŒããã¿ãã³ãåçã»ã«ããŒã¹èã®è¡šé¢ã«ã³
ãŒãã£ã³ã°ããæ¹æ³ãææ¡ãããŠãããã被èã®å®å®æ§
ãæ»
èã®æ¹æ³ãéå®ããããªã©ã®åé¡ç¹ãããããŸãã
ç¹éæïŒïŒâïŒïŒïŒïŒå·å
¬å ±ã«åçã»ã«ããŒã¹èã«ã€ãœ
ã·ã¢ããŒããã¬ããªããŒãåå¿ãããæ¹æ³ããç¹éæïŒ
ïŒâïŒïŒïŒïŒïŒïŒå·å
¬å ±ã«ããªããžå€ãä»ããŠããªããŒ
é
žãååŠçã«çµåãããæ¹æ³ãææ¡ãããŠããããåå¿
ç©è³ªå®å®æ§ãåã³åå¿å·¥çšã®è€éããªã©ã®åé¡ããããOn the other hand, various methods have been proposed for modifying the blood affinity of regenerated cellulose membranes. For example, a method of imparting antithrombotic properties by heparinizing the membrane surface has been published in Jikai 51-194.
However, it has not been put into practical use because sufficient effects cannot be obtained and the cost is relatively high. Also,
Methods of coating the surface of regenerated cellulose membranes with various polymers and vitamins have also been proposed, but there are problems such as the stability of the coating and limitations on sterilization methods. Also,
JP-A No. 61-8105 discloses a method of reacting an isocyanate prepolymer with a regenerated cellulose membrane.
0-118203 proposes a method of chemically bonding polymeric acids via a bridging agent, but there are problems such as stability of reactants and complexity of the reaction process.
ããã«ãç¹éæïŒïŒâïŒïŒïŒïŒïŒïŒå·å
¬å ±ã«ãžãšãã«ã¢
ãããšãã«ã»ã«ããŒã¹çã®æ¹å€ã»ã«ããŒã¹ãçšããŠè£œè
ããéæèãææ¡ãããŠããããè¡æ¶²ååºã軜æžããé¢
ã§ã®æ¹è¯ã¯ååãšã¯èšããªããFurthermore, although a dialysis membrane made using modified cellulose such as diethylaminoethyl cellulose has been proposed in JP-A-61-113459, it cannot be said that the improvement in reducing blood coagulation is sufficient.
äžèšã®ããã«ãåçã»ã«ããŒã¹èã®è¡æ¶²èŠªåæ§ãåäžã
ããè©Šã¿ã«ã¯ãäžé·äžçããããããã§ãæ¬çºæã®ç®ç
ã¯ãåçã»ã«ããŒã¹ãããªãé«ååèã®åªããéææ§èœ
ãæãªãããšãªããè¡æ¶²èŠªåæ§ãåäžããããæ¹è³ªãã
ãåçã»ã«ããŒã¹èåã³ãã®è£œé æ³ãæäŸããããšã«ã
ããAs mentioned above, attempts to improve the blood affinity of regenerated cellulose membranes have advantages and disadvantages. Therefore, an object of the present invention is to provide a modified regenerated cellulose membrane that has improved blood affinity without impairing the excellent dialysis performance of a polymer membrane made of regenerated cellulose, and a method for producing the same. .
åé¡ç¹ã解決ããããã®æ段åã³äœçš
åçã»ã«ããŒã¹èãçšããå Žåçããè£äœæåã®æŽ»æ§å
ãçœè¡çã®äžéæ§æžå°ã«ã¯ãèè¡šé¢ã®æ°Žé
žåºãé¢äžããŠ
ãããšèããããŠãããäžæ¹ããã®èè¡šé¢ã®æ°Žé
žåºã¯çš®
ã
ã®å®èœåºãšåå¿ãååéãçµåããäºãã§ãããçµå
ããååéã¯ãèäžã®æ°Žé
žåºããã¹ãã³ã°ããè£äœèçœ
ãè¡çãšæ°Žé
žåºã®çŽæ¥ã®æ¥è§Šã劚ãããããã«ãããè£
äœæåã®æŽ»æ§åãæå¶ã§ããã ãã§ãªããèè¡šé¢ã®ç©ç
ååŠçæ§è³ªã«åœ±é¿ãäžããä»ã®è¡æ¶²èŠªåæ§ããæ¹åã§ã
ããååéã®æ§é åã³å®èœåºã«ã¯å€ãã®çµåããå¯èœã§
ããããçäœå®å
šæ§ãçäœèŠªåæ§ãçµæžæ§ãååŠåå¿æ§
ãªã©ãèæ
®ããçš®ã
ç 究ãéããçµæãæ¬çºæã®å®æã«
å°ã£ããããªãã¡ãæ¬çºæã§ã¯ãåçã»ã«ããŒã¹èã®å°
ãªããšãè¡æ¶²ãšæ¥è§Šããèé¢ã«èèªæã«ã«ãã³é
žç¡æ°Žç©
ããšã¹ãã«çµåãããããšãç¹åŸŽãšããæ¹è³ªãããåç
ã»ã«ããŒã¹èãæäŸãããèèªæã«ã«ãã³é
žç¡æ°Žç©åã³
ãšã¹ãã«å觊åªãåå¿åªäœã«æº¶è§£ãŸãã¯åæ£ããã溶液
ã§åçã»ã«ããŒã¹èãåŠçããããšã«ãããèèªæã«ã«
ãã³é
žç¡æ°Žç©ãšã®ãšã¹ãã«ååå¿ãè¡ãããšãç¹åŸŽãšã
ãæ¹è³ªãããåçã»ã«ããŒã¹èã®è£œé æ¹æ³ãæäŸããã
ãMeans and Actions for Solving the Problems It is believed that the hydroxyl groups on the membrane surface are involved in the activation of complement components and the temporary decrease in white blood cells that occur when a regenerated cellulose membrane is used. On the other hand, the hydroxyl groups on the surface of this membrane can react with various functional groups to bond molecular chains. The bound molecular chains mask the hydroxyl groups on the membrane, preventing direct contact between the hydroxyl groups and complement proteins and blood cells. This not only suppresses the activation of complement components, but also affects the physicochemical properties of the membrane surface and improves other blood affinities. Although many combinations of molecular chain structures and functional groups are possible, we have completed the present invention after conducting various studies in consideration of biosafety, biocompatibility, economic efficiency, chemical reactivity, etc. It was. That is, the present invention provides a modified regenerated cellulose membrane characterized in that an aliphatic carboxylic anhydride is ester bonded to at least the surface of the regenerated cellulose membrane that comes into contact with blood. A modified regenerated cellulose membrane characterized in that an esterification reaction with an aliphatic carboxylic acid anhydride is carried out by treating the regenerated cellulose membrane with a solution in which a substance and an esterification catalyst are dissolved or dispersed in a reaction medium. A manufacturing method is provided.
æ¬çºæã§äœ¿çšãããåçã»ã«ããŒã¹ããšã¯ã倩ç¶ã»ã«ã
ãŒã¹ãäžæŠååŠçã«æãã¯ç©ççã«å€åãããåŸåçã
ããã®ã§ãã£ãŠãäŸãã°ãé
ã¢ã³ã¢ããŠã æ³åçã»ã«ã
ãŒã¹ããã¹ã³ãŒã¹ã¬ãŒãšã³ãã»ã«ããŒã¹ãšã¹ãã«ã鹞å
ãããã®ãå«ãŸããããéææ§èœåã³é·å¹Žã®å®çžŸã«ãã
è£ä»ãããé«ãå®å
šæ§çããé
ã¢ã³ã¢ããŠã æ³åçã»ã«
ããŒã¹ã奜ãã§çšãããããThe "regenerated cellulose" used in the present invention is natural cellulose that has been chemically or physically changed and then regenerated. However, copper ammonium regenerated cellulose is preferably used due to its dialysis performance and high safety backed by many years of experience.
åçã»ã«ããŒã¹ã®åœ¢ç¶ã¯ãå¹³èãŸãã¯äžç©ºç³žèçäœãã®
圢ç¶ã«æåããããã®ãçšããäºãã§ããããäžç©ºç³žè
ã奜ãŸãããäŸãã°ãç¹å
¬æïŒãâïŒïŒïŒïŒïŒå·å
¬å ±å
ã³ç¹éæïŒïŒâïŒïŒïŒïŒïŒïŒå·å
¬å ±ã«é瀺ãããŠããã
ããªãèåãæ°ÎŒãïŒïŒÎŒã§ãããå€åŸãïŒïŒÎŒãæ°çŸ
ÎŒã®çå圢ã®æšªæé¢ãæããäžç©ºç³žèçãçšãããããThe regenerated cellulose may be formed into any shape such as a flat membrane or a hollow fiber membrane, but a hollow fiber membrane is preferred. For example, as disclosed in Japanese Patent Publication No. 50-40168 and Japanese Unexamined Patent Publication No. 59-204912, the film thickness is from several ÎŒ to 60 ÎŒ and the outer diameter is from 10 ÎŒ to several hundred ÎŒ. A hollow fiber membrane having a surface or the like is used.
æ¬çºæã§ã¯ãäžè¿°ã®åçã»ã«ããŒã¹èã«èèªæã«ã«ãã³
é
žç¡æ°Žç©ããšã¹ãã«çµåãããé
žèã®æ¹è³ªãè¡ãªããã
ã®ãããªèèªæã«ã«ãã³é
žãšããŠã飜åãŸãã¯äžé£œåè
èªé
žãèèªæãžã«ã«ãã³é
žçã®èèªæã«ã«ãã³é
žãæã
ããããèäžã®æ°Žé
žåºã®ãã¹ãã³ã°å¹æãããèèªæã«
ã«ãã³é
žãšããŠãççŽ æ°ïŒå以äžã®ãã®ã奜ãŸãããå
èé
žãã«ããã³é
žããšãã³ãé
žãã«ããªã«é
žããã©ã«ãŽ
ã³é
žãã«ããªã³é
žããŠã³ãã·ã«é
žãã©ãŠãªã³é
žãããªã
ã·ã«é
žãããªã¹ãã³é
žããã³ã¿ãã·ã«é
žããã«ããã³é
ž
ãããã¿ãã·ã«é
žãã¹ãã¢ãªã³é
žããããã«ã³é
žãã¢ã©
ãã³é
žãããã³é
žããªã°ãã»ãªã³é
žçã®é£œåèèªé
žããª
ã¬ã€ã³é
žããšã©ã€ãžã³é
žãã»ãã¬ã€ã³é
žããšã«ã«é
žãã
ã©ã·ãžã³é
žããœã«ãã³é
žããªããŒã«é
žããªã«ã³é
žãã¢ã©
ããã³é
žçã®äžé£œåèèªé
žãåã³ã°ã«ã¿ã«é
žãã¢ãžãã³
é
žããã¡ãªã³é
žãã¹ããªã³é
žãã¢ãŒã©ã€ã³é
žãã»ãã·ã³
é
žçã®èèªæãžã«ã«ãã³é
žçãçšãããããIn the present invention, an aliphatic carboxylic acid anhydride is ester bonded to the above-mentioned regenerated cellulose membrane to modify the acid membrane. Examples of such aliphatic carboxylic acids include aliphatic carboxylic acids such as saturated or unsaturated fatty acids and aliphatic dicarboxylic acids. From the masking effect of hydroxyl groups on the film, the aliphatic carboxylic acids preferably have 5 or more carbon atoms, such as valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, and tridecyl. Acids, saturated fatty acids such as myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, nonadecanoic acid, arachidic acid, behenic acid, lignoceric acid, oleic acid, elaidic acid, cetoleic acid, erucic acid, brassic acid, sorbic acid , unsaturated fatty acids such as linoleic acid, linoleic acid, and arachidonic acid, and aliphatic dicarboxylic acids such as glutaric acid, adipic acid, pimelic acid, superric acid, azelaic acid, and sebacic acid.
ãã®ãããªèèªæã«ã«ãã³é
žã¯ãæ¯æ§ã匱ããçäœå
ã§
代è¬ãããããèç©ãèµ·ããªãããããã£ãŠèã«ä»çã
ãæªåå¿ç©ã溶åºããŠããããã¯äœããã®æäœã§ãšã¹ã
ã«çµåãéè£ããŠãè¡Â°æ¶²äžãžæ··å
¥ããå Žåãå®å
šæ§ã
é«ããSuch aliphatic carboxylic acids have low toxicity and are metabolized within the body, so they do not accumulate. Therefore, it is highly safe even if unreacted substances attached to the membrane are eluted or ester bonds are cleaved by some operation and mixed into blood.
æ¬çºæã§èšãååéãšã¯ãèè¡šé¢ã«å°ãªããšãïœãååŠ
çµåããææ©ååç©ã§ãããæ¬çºæã§ã¯ããšã¹ãã«çµå
ããèèªæã«ã«ãã³é
žæ®åºãçžåœããããŸããäžèšã®ã
ãã«å®èœåºãšãªãã«ã«ããã·ã«åºåã³ãã®é
žèªå°äœåºã
å¿
ãããïŒåã ãã§ãªãéå®ãããããšã¯ãªãããå€å®
èœã®èèªæã«ã«ãã³é
žã®å Žåãèè¡šé¢ã®æ°Žé
žåºãšåå¿ã
ãåã«ã«ã«ãã³é
žåå¿ã®åå¿ã«ããã«ã«ãã³é
žã®é«åå
åãé²ã¿ããšã¹ãã«åã®åå¿æ§äœäžãçããããšããã
ããŸããå€å®èœã®ã«ã«ãã³é
žã®å Žåãäžç®æ以äžã§è¡šé¢
ã«çµåããã«ãŒãç¶ã®ååéã圢æããå¯èœæ§ãããã
ãåŸè¿°ããããã«ãååéã¯ãäžç«¯ãè¡šé¢ã«çµåããŠã
ãã»ãã奜ãŸãããã¢ãã«ã«ãã³é
žããã奜ãã§çšãã
ãããThe molecular chain referred to in the present invention is an organic compound in which at least i is chemically bonded to the membrane surface, and in the present invention, it corresponds to an aliphatic carboxylic acid residue having an ester bond. In addition, as mentioned above, the number of carboxyl groups and acid derivative groups serving as functional groups is not limited to just one, but in the case of polyfunctional aliphatic carboxylic acids, before reacting with the hydroxyl groups on the membrane surface, In addition, polymerization of carboxylic acids may progress due to reactions between carboxylic acids, resulting in a decrease in esterification reactivity. In addition, in the case of polyfunctional carboxylic acids, there is a possibility of forming a loop-shaped molecular chain bonded to the surface at three or more places, but as will be explained later, it is better for the molecular chain to have one end bonded to the surface. Preferably, monocarboxylic acids are used.
ãããã®ã«ã«ãã³é
žã¯ãã«ã«ãã³é
žç¡æ°Žç©ãçšããŠãå
çã»ã«ããŒã¹èã®è¡šé¢ã«ãšã¹ãã«çµåããããããThese carboxylic acids are ester bonded to the surface of the regenerated cellulose membrane using carboxylic anhydrides.
åçã»ã«ããŒã¹èã®è¡šé¢ãžã®ãšã¹ãã«çµåã¯ãèè¡šé¢ã«
ååšããæ°Žé
žåºãšã®ãšã¹ãã«ååå¿ã«ãã£ãŠè¡ãããå
¬
ç¥ã®äœååã®ã¢ã«ã³ãŒã«ãšäœååã®ã«ã«ãã³é
žç¡æ°Žç©ãš
ã®åå¿ãé©çšã§ãããåŠçæ¡ä»¶ãšããŠãåçã»ã«ããŒã¹
èã®ç©æ§ã«åœ±é¿ãäžããªãããã«ãåŠç枩床ãäœãæã
ãåŠçæéãã§ããã ãçãããäºã奜ãŸãããããã
ã®äºé
ã¯çµæžæ§ã®é¢ãããæå©ã§ããããšã¹ãã«å觊åª
ã䜿çšããŠãšã¹ãã«åãä¿é²ããããšã奜ãŸãããEster bonding to the surface of the regenerated cellulose membrane is performed by an esterification reaction with hydroxyl groups present on the membrane surface, and a known reaction between a low-molecular alcohol and a low-molecular carboxylic acid anhydride can be applied. As for the treatment conditions, it is preferable to keep the treatment temperature low and the treatment time as short as possible so as not to affect the physical properties of the regenerated cellulose membrane. These matters are advantageous from an economic point of view, and it is preferable to use an esterification catalyst to promote esterification.
åå¿ãä¿é²ããããšã¹ãã«å觊åªãšããŠãç¡«é
žãïœâã
ã«ãšã³ã¹ã«ãã³é
žãå¡©åäºéãé
¢é
žãããªãŠã ãããªãž
ã³ãïŒâãžã¡ãã«ã¢ããããªãžã³ãïŒâãããªãžã³ããª
ãžã³çãæãããããæ¬çºæã§ã¯ããããã®è§Šåªãåç¬
ãŸãã¯é©å®çµåããŠçšããããšãã§ããããåå¿ãåæ»
ã«é²ããç¹ãåå¿åŸã®é€å»ã®ç¹ãããåå¿åªäœã«å¯æº¶ã®
ãã®ãã§ããã ãå°é䜿çšããäºã奜ãŸãããExamples of the esterification catalyst that promotes the reaction include sulfuric acid, p-toluenesulfonic acid, zinc chloride, sodium acetate, pyridine, 4-dimethylaminopyridine, and 4-pyrrolidinepyridine. In the present invention, these catalysts can be used alone or in appropriate combinations, but from the viewpoint of smooth reaction and removal after the reaction, it is preferable to use as little as possible of a catalyst that is soluble in the reaction medium.
ãã®ãããªèŠ³ç¹ãããã«ã«ãã³é
žç¡æ°Žç©ãïŒâãžã¡ãã«
ã¢ããããªãžã³åã³ïŒãŸãã¯ïŒâãããªãžãããªãžã³ã§
ãšã¹ãã«ååå¿ããããæ¹æ³ã奜ãã§çšããããæ²æŸ±ç©
ãçæããäºããªããå³ã¡ãè现åã«ãšã蟌ãŸããæ²æŸ±
ç©ããããšãéææ§èœã®äœäžãåŒãèµ·ãããããã¯äººå·¥
èåšãšããŠã®äœ¿çšæã«ãè¡æ¶²äžãžæ··å
¥ã®æããããã奜
ãŸãããªãããŸããåŠçåŸã¯é€èã®ããæ¿Ÿéæäœãæ®é
ã«è¡ãªãããããæ²æŸ±ç©ã¯ãã®æäœãå°é£ãªãã®ãšãã
ãFrom this point of view, a method of esterifying a carboxylic acid anhydride with 4-dimethylaminopyridine and/or 4-pyrrolidinopyridine is preferably used, and does not generate a precipitate. That is, if there is a precipitate trapped in the membrane pores, it may cause a decrease in dialysis performance or may be mixed into blood when used as an artificial organ, which is not preferable. Further, after treatment, a filtration operation is normally carried out for sterilization, but the precipitate makes this operation difficult.
åå¿åªäœãšããŠã¯ãèèªæã«ã«ãã³é
žç¡æ°Žç©ãšåå¿ããª
ãããšããšã¹ãã«å觊åªã倱掻ãããªãããšãåçã»ã«
ããŒã¹èãããªãé«ååèã«å€§ããªåœ¢æ
å€åãçããã
ããªãããšãå¿
èŠã§ãããThe reaction medium must not react with the aliphatic carboxylic acid anhydride, do not deactivate the esterification catalyst, and do not cause any major morphological changes in the polymer membrane made of regenerated cellulose membrane.
åŸã£ãŠãåå¿åªäœãšããŠãäžèšã®èŠä»¶ãæºãããèèªæ
ã«ã«ãã³é
žç¡æ°Žç©åã³ãšã¹ãã«å觊åªãåæ£ãŸãã¯æº¶è§£
ããã溶å€ã¯ãå
šãŠçšãããããåå¿ã®åäžæ§ãåæ»æ§
åã³åå¿åŸã®é€å»ãããèèªæã«ã«ãã³é
žç¡æ°Žç©åã³ãš
ã¹ãã«å觊åªã溶解ããã溶å€ã奜ãŸããããã®ãããª
åå¿åªäœãšããŠãäŸãã°ãïœâãããµã³ãïœâãžãã¿ã³
ãã·ã¯ããããµã³ãç³æ²¹ãšãŒãã«ãç³æ²¹ãã³ãžã³ããã³
ãŒã³ããã«ãšã³çã®çåæ°ŽçŽ é¡ãã¢ã»ãã³ãã¡ãã«ãšã
ã«ã±ãã³çã®ã±ãã³é¡ãé
¢é
žã¡ãã«ãé
¢é
žãšãã«ãé
¢é
ž
ãããã«çã®ãšã¹ãã«é¡ããšãã«ãšãŒãã«ãã€ãœããã
ã«ãšãŒãã«ããžãªããµã³çã®ãšãŒãã«é¡ãïœãïŒïŒïŒâ
ïŒâãžã¯ããâïŒïŒïŒïŒïŒâããªãã«ãªããšã¿ã³ãããª
ã¯ãããã«ãªãã¡ã¿ã³ãâ ãTherefore, any solvent that satisfies the above requirements and that can disperse or dissolve the aliphatic carboxylic acid anhydride and the esterification catalyst can be used as the reaction medium. A solvent that dissolves the aliphatic carboxylic acid anhydride and the esterification catalyst is preferred from the viewpoint of reaction uniformity, smoothness, and post-reaction removal. Examples of such a reaction medium include n-hexane, n-hebutane, and cyclohexane. , hydrocarbons such as petroleum ether, petroleum benzine, benzene and toluene, ketones such as acetone and methyl ethyl ketone, esters such as methyl acetate, ethyl acetate and propyl acetate, ethers such as ethyl ether, isopropyl ether and dioxane, l , 1.2-
1-dichloro-1,2,2-trifluoroethane, trichlorofluoromethane, â .
ïŒïŒïŒïŒïŒâããã©ã¯ããâïŒïŒïŒâãžãã«ãªããšã¿ã³
çã®å¡©ååŒåçåæ°ŽçŽ çãæããããããããã®åå¿åª
äœã¯ãåç¬ãŸãã¯æ··åããŠäœ¿çšã§ãããçäœãžã®å®å
šæ§
ãåå¿åŸã®é€å»ã®èŠ³ç¹ãããå¡©ååŒåçåæ°ŽçŽ ãç¹ã«ïŒ
ïŒïŒïŒïŒâãã¯ããâïŒïŒïŒïŒïŒâïŒãªãã«ãªããš
ã¿ã³ãå«ãåå¿åªäœã奜ãŸãããïŒïŒïŒïŒïŒâïŒãªã¯ã
ããŒïŒïŒïŒãïŒâããªãã«ãªããšã¿ã³ãšã¢ã»ãã³ã®æ··å
溶åªã奜ãã§çšãããããExamples include chlorofluorinated hydrocarbons such as 1.2.2-tetrachloro-1,2-difluoroethane. These reaction media can be used alone or in mixtures. From the viewpoint of biological safety and post-reaction removal, chlorinated fluorinated hydrocarbons, especially 1
, 1.2-trichloro-1,2,2-)trifluoroethane is preferred, and a mixed solvent of 1.1.2-)lichloro-1.2ã2-trifluoroethane and acetone is preferred. It is used in
åçã»ã«ããŒã¹èãåŠçããæ¹æ³ãšããŠã¯çš®ã
ã®æ¹æ³ã
ãããå³ã¡ãèèªæã«ã«ãã³é
žç¡æ°Žç©åã³ãšã¹ãã«å觊
åªãåå¿åªäœã«åæ£ãŸãã¯æº¶è§£ãããåŠç液ã«ãåçã»
ã«ããŒã¹èãæå
¥ãæªæããæ¹æ³ãåŠç液ãå
å¡«ãã浞
挬槜å
ã«é«ååèã浞挬ãããæ¹æ³ãé«ååèãå
å¡«ã
ãåŠç槜ã«åŠç液ã«åŸªç°ããæ¹æ³ãæ¡çšã§ãããããã«
ãåçã»ã«ããŒã¹ãããªãé«ååèãéæåšçã«çµã¿ç«
ãŠãåŸãå°ãªããšãè¡æ¶²ãæµéãããåŽã«ãåŠç液ã埪
ç°ããããŸãã¯å
å¡«ããŠæŸçœ®ãããæ¹æ³ãåœç¶æ¡çšã§ã
ããThere are various methods for treating regenerated cellulose membranes. That is, a method in which a regenerated cellulose membrane is added to and stirred in a treatment solution in which an aliphatic carboxylic acid anhydride and an esterification catalyst are dispersed or dissolved in a reaction medium, and a polymer membrane is immersed in an immersion tank filled with the treatment solution. Alternatively, a method may be adopted in which the processing solution is circulated through a processing tank filled with a polymer membrane. Furthermore, after assembling a polymer membrane made of regenerated cellulose into a dialyzer or the like, it is naturally possible to adopt a method in which a treatment liquid is circulated or filled at least on the side through which blood flows and left to stand.
ãšã¹ãã«ååå¿çµäºåŸãåçã»ã«ããŒã¹èãåŠç液ãšå
é¢ãããåå¿è©Šè¬ããšã¹ãã«å觊åªãŸãã¯å¯åå¿çæç©
çãèã«æ®çããªãå Žåã«ã¯çç¥ãããããéåžžããã
ãé€å»ããããæŽæµãè¡ãããããã®æŽæµæäœã«ã¯ãå
å¿ã«äœ¿çšãã溶åªããŸãã¯ã¡ãã«ã¢ã«ã³ãŒã«ããšãã«ã¢
ã«ã³ãŒã«ãªã©åçã»ã«ããŒã¹èã«å€§ããªåœ¢æ
å€åãèµ·ã
ãããªã溶åªãçšãã浞挬æœåºããŸãã¯ãœãã¯ã¹ã¬ãŒæœ
åºãè¡ããããæåŸã«ãæžå§ä¹Ÿç¥ãé颚也ç¥çã«ããæ®
ç溶åªã®é€å»ãè¡ããããAfter the esterification reaction is completed, the regenerated cellulose membrane is separated from the processing solution and is omitted if no reaction reagents, esterification catalysts, or side reaction products remain in the membrane, but washing is usually performed to remove these. be exposed. In this washing operation, immersion extraction or Soxhlet extraction is performed using the solvent used in the reaction or a solvent that does not cause a major change in the form of the regenerated cellulose membrane, such as methyl alcohol or ethyl alcohol. Finally, residual solvent is removed by vacuum drying, blow drying, or the like.
ãã®ããã«ããŠèè¡šé¢ããšã¹ãã«åãããåçã»ã«ããŒ
ã¹ãããªãé«ååèã§ã¯ãå®æœäŸã«ç€ºãããããã«çšã
ãé«ååèã®åªããéææ§èœãæãªãããããšãªããè£
äœæåã®æŽ»æ§åäœçšãæå¶ãããçœè¡çäžéæ§æžå°ã軜
埮ã«ãªãããã®ãããªå¹æã¯ãæ¬çºæã«æŒããŠãšã¹ãã«
ååå¿ãé«ååèè¡šé¢ã§ã®ã¿èµ·ãããèå
éšã®ååŠçå
ã³ç©ççæ§é ãç¶æãããŠãããããšèããããããŸã
ãè¡šé¢ã«ãšã¹ãã«åãããéããè¡šé¢ã®ç©çååŠçåã³
çç©ååŠçæ§è³ªãæ¹è¯ããã«ååãªéã§ããããæ°Žãç©
質ã®ééã«æªåœ±é¿ãäžããªãçšåºŠã®æ¥µïœïœã§ãããããš
èãããããA polymer membrane made of regenerated cellulose whose membrane surface has been esterified in this manner has the ability to activate complement components without impairing the excellent dialysis performance of the polymer membrane used, as shown in the examples. suppressed, and the transient decrease in white blood cells becomes slight. This effect is thought to be due to the fact that in the present invention, the esterification reaction occurs only on the surface of the polymer membrane, and the chemical and physical structure inside the membrane is maintained. In addition, the amount of esterification on the surface is sufficient to improve the physicochemical and biochemical properties of the surface, but is so small that it does not adversely affect the permeation of water or substances. Conceivable.
èè¡šé¢ã®ç©çååŠçåã³çç©ååŠçæ§è³ªã®æ¹è¯ã®å¹æã¯
ãä»ã®è¡æ¶²èŠªåæ§ã«ãææã§ãããå³ã¡èèªé
žããšã¹ã
ã«çµåãããçæ°Žæ§ååéã®å Žåãè¡æŒ¿ã¿ã³ãã¯ã®ãã¡
ã¢ã«ããã³ãéžæçã«åžçããããã¢ã«ããã³ã¯ãè¡æ¶²
äžã§èèªé
žã®ãã£ãªã¢ãŒãšããŠåããåå軞äžå¿ã«çæ°Ž
æ§ã®ãã±ãããæããŠãããšããããŠããããã®ãã±ã
ãã«ãçæ°Žæ§ã®ååéããçµåããããéžæçãªåžçã
èµ·ãããšèããããããã®ããã«ã¢ã«ããã³ãéžæåžç
ããè¡æ¶²æ¥è§Šè¡šé¢ã§ã¯ãè¡æ¶²ååºãèµ·ããé£ããšèãã
ããŠããããã®çè«çæ ¹æ ãšããŠããã£ããªããŒã²ã³ã
å
ç«ã°ãããªã³ã®ãããªç³éãæããèçœè³ªã¯ããã®ç³
éãä»ããŠè¡å°æ¿ãšçµåããããã¢ã«ããã³ã¯ããã®ã
ããªç³éãæãããè¡å°æ¿ãšã®ç¹ç°çãªçµåãèµ·ãããª
ããããè¡æ¶²äžããã¢ã«ããã³ãåªå
çã«åžçããè¡æ¶²
æ¥è§Šè¡šé¢ã§ã¯è¡æ¶²ååºãèµ·ããé£ããšèããããŠãããThe effects of improving the physicochemical and biochemical properties of the membrane surface can also be noted on other blood affinities. That is, in the case of a hydrophobic molecular chain in which a fatty acid is ester bonded, albumin among plasma proteins is selectively adsorbed. Albumin functions as a carrier of fatty acids in the blood and is said to have a hydrophobic pocket at the center of its molecular axis. It is thought that selective adsorption occurs because hydrophobic molecular chains bind to this pocket. It is thought that blood coagulation is unlikely to occur on blood contact surfaces where albumin is selectively adsorbed in this manner. The rationale for this is that proteins with sugar chains such as fibrinogen and immunoglobulin bind to platelets via these sugar chains, but albumin does not have such sugar chains and has a unique bond with platelets. Since no binding occurs, it is thought that blood coagulation is unlikely to occur on blood contact surfaces that preferentially adsorb albumin from blood.
äžèšã®ãããªã¢ã«ããã³ã®éžæåžçã«ã¯ãååéãäžç®
æ以äžã§é«ååèè¡šé¢ã«çµåããéã®éåãæå¶ããã
ç¶æ
ããããïŒç«¯ãçµåãä»ã®æ«ç«¯ãèªç±ã«éåã§ãã
ã»ãã奜ãŸãããããã¯èªç±ãªååéã®ã»ãããèã®å®
質衚é¢ãé®èœããå®è³ªè¡šé¢ã§ã®ãã®ä»ã®èçœè³ªã®åžçã
æå¶ããããããšèããããããŸãåãå¹æã«ããè£äœ
èçœã®åçã»ã«ããŒã¹èãšã®çŽæ¥æ¥è§Šã劚害ããããã®
掻æ§åãæå¶ããããFor the selective adsorption of albumin as described above, the molecular chains are bound to the polymer membrane surface at three or more places, and rather than the state where chain movement is suppressed, one end is bound and the other end can move freely. That's preferable. This is thought to be because free molecular chains shield the real surface of the membrane, suppressing adsorption of other proteins on the real surface. The same effect also prevents the direct contact of complement proteins with the regenerated cellulose membrane, suppressing their activation.
æ²»çã«äœ¿çšããåã«æ»
èæäœãå¿
èŠã§ããããæ¬çºæã®
åçã»ã«ããŒã¹èã¯ãåçš®ã®æ»
èæ³ãå©çšããããšãã§
ãããå³ã¡ãçµã¿èŸŒãã éæåšãããã®ãŸãŸä¹Ÿç¥ç¶æ
ã§
æ»
èããããšãã¬ã³ãªããµã€ãã¬ã¹æ»
èãé«å§èžæ°æ»
è
ãåã³ã¬ã³ãâç·æ»
èçãå©çšã§ãããŸãã¯çµã¿èŸŒãã
éæåšã«æ°ŽãŸãã¯ççé£å¡©æ°Žãªã©ãå
å¡«ããåŸæ»
èãã
ãé«å§èžæ°æ»
èããŸãã¯ã¬ã³ãâç·æ»
èãªã©ãå©çšã§ã
ããAlthough sterilization is required before use for treatment, the regenerated cellulose membrane of the present invention can be sterilized using various sterilization methods. That is, the incorporated dialyzer can be sterilized in a dry state, ethylene oxide gas sterilization, high-pressure steam sterilization, gamma ray sterilization, etc., or the incorporated dialyzer can be sterilized with water or physiological saline, etc. Sterilization, high pressure steam sterilization, gamma ray sterilization, etc. can be used.
ãã®ãããªæ»
èæäœã«ãã£ãŠãæ¹è¯ãããè¡æ¶²èŠªåæ§ã
å€åããããšã¯ãªããSuch sterilization procedures do not alter the improved hemocompatibility.
次ã«ãå®æœäŸã«ããæ¬çºæã®å
容ãããã«è©³çŽ°ã«è¿°ã¹ã
ãNext, the content of the present invention will be described in more detail with reference to Examples.
ãªã以äžã®å®æœäŸäžã«èšèŒãããŠãã枬å®é
ç®ã¯ãåã
次ã®æ¹æ³ã§æž¬å®ãããã®ã§ãããNote that the measurement items described in the following examples were measured by the following methods.
ïŒïŒïŒéæ°Žé
ïŒïŒïŒæ¬ã®äžç©ºç¹ç¶ã®æã®äž¡ç«¯ãæ¥çå€ã§åºå®ããã¢ãž
ã¥ãŒã«ãäœããäžç©ºéšã«æ°ŽãæºãããåŸãç端ãéãã
éå£éšããïŒïŒïŒïœïœïŒšïœã®å§åããããªããæ°Žãå
¥ã
ãåäœæéåœããã®éæ°Žéã枬å®ãããäžç©ºç¹ç¶ã®èé¢
ç©ã¯ãå
åŸãåã³ã¢ãžã¥ãŒã«ã®æå¹é·ã枬ã£ãŠèšç®ã«ã
ãæ±ããã(1) Water permeability: Make a module by fixing both ends of a bundle of 100 hollow fibers with adhesive, fill the hollow part with water, close one end,
Water is poured through the opening while applying a pressure of 200 mmHg, and the amount of water permeation per unit time is measured. The membrane area of the hollow fiber is calculated by measuring the inner diameter and the effective length of the module.
ïŒïŒïŒã¯ãªã¢ã©ã³ã¹
ïŒïŒïŒãšåæ§ã®ã¢ãžã¥ãŒã«ãäœããæ°Žã®ä»£ããã«ïŒïŒïŒ
ïŒïŒïœïœã®å°¿çŽ 氎溶液ããŸãã¯ïŒïŒïŒïŒïœïœã®ãã¿ãã³
âïŒâïŒãïŒïŒ¶ïŒ¢ïŒ©â¡ïŒæ°Žæº¶æ¶²ãçšããŠãïŒïŒïŒãšå
æ§ã®æ¹æ³ã§éæ液äžã®æ¿åºŠããåžå
床ããæ±ããŠã次åŒ
ããã¯ãªã¢ã©ã³ã¹ãèšç®ããã(2) Make a module similar to Clearance (1), and use 110 ml instead of water.
Using a 00pp urea aqueous solution or a 1100pp vitamin B-1''2 (VBIâ¡) aqueous solution, determine the concentration in the dialysate from the absorbance in the same manner as in (1), and calculate the clearance using the following formula. .
ã¯ãªã¢ã©ã³ã¹ïŒ
ïŒéæ液äžã®æ¿åºŠïŒÃïŒïŒåéå
ããã®éæ液éïŒïŒïŒ
ïŒè£äœæ¶è²»ç
è¡æž
ïŒåœããïŒïŒïœïŒ©ïœïœã®è¡šé¢ç©ã«ãªããã
ã«åçã»ã«ããŒã¹èãæå
¥ããïŒïŒâã§ïŒæéæ¯çªãã
åŸãè¡æž
äžã«æ®åããè£äœåãã¡ã€ã€ãŒçã®æ¹æ³ïŒÎµïœ
ïœïœ
ïœïœïœïœ
ïœïœïœïœãããïœïœïœïœïœïœïœïœ
ïœïœïœ
ïœïœïœïŒããïœãïŒãïŒãïŒãããClearance = (concentration in dialysate) x (volume of dialysate per minute) (3
) Complement consumption rate After adding a regenerated cellulose membrane to a surface area of 80 cIll per serum ITII+ and shaking at 37°C for 1 hour, the remaining complement in the serum was determined by the method of Mayer et al. (εx
peripheral immunochemistry
try+ p 1 3 3.
ïœïœïœïœïœãããïŒïŒïŒïŒãïŒã«ããïŒïŒïŒ
溶è¡è£äœ
䟡ã§æ±ããã³ã³ãããŒã«ããã®äœäžãè£äœæ¶è²»çã§è¡šã
ããThomas, 1961), the hemolytic complement value was determined as 50%, and the decrease from the control was expressed as the complement consumption rate.
ïŒïŒïŒïŒ¥ïŒ©ïŒ¡ãïŒé
µçŽ å
ç«æž¬å®ïŒæ³
äžç©ºç¹ç¶å
ã«ãŠãµã®è¡æŒ¿ãå
å¡«ããïŒïŒâã§ïŒæéã€ã³
ãã¥ããŒãããããã®åŸãŠãµã®è¡éœãæŒãåºãã
ãããã¡ãŒã§æ°åæŽæµããããã®äžç©ºç¹ç¶å
è¡šé¢ã«è¡æŒ¿
ãåžçããããµã³ãã«å
ã«ããããã¢ã«ããã³ãã€ã ã
ã°ãããªã³ã»ãžãŒïŒïŒ©ïœïŒ§ïŒããã£ããªããŒã²ã³ã«å¯Ÿã
ããã«ãªãã·ããŒãŒæšèæäœïŒã«ãã«ç€Ÿè£œïŒãå
å¡«ãã
åžçããŠããèçœè³ªãšæåæäœåå¿ãããããã
ãã¡ãŒã§å
åæŽæµããåŸãäžç©ºç¹ç¶ãïŒïœïœé·ã«çŽ°æã
ãããªãšãã¬ã³ç®¡ã«å
¥ããããã®ããªãšãã¬ã³ç®¡ã«ãã«
ãªãã·ããŒãŒã®åºè³ªã§ããïŒâïŒïœâããããã·ãã§ã
ã«ïŒããããªã³é
žåã³éé
žåæ°ŽçŽ æ°Žãå ããé
µçŽ åå¿ã
ïŒæéè¡ããããŠãçæããé
žåç©ãè¢å
åå
ã§æž¬å®ã
ãã(4) EIA (Enzyme Immunoassay) Method Fill the hollow fiber with rabbit plasma and incubate at 37°C for 1 hour. Afterwards, extrude the rabbit blood and add PBS.
Wash several times with buffer. Peroxidase-labeled antibodies (manufactured by Capel) against albumin, immunoglobulin G (IgG), and fibrinogen were filled into the samples with plasma adsorbed on the inner surface of the hollow fibers.
Antigen-antibody reaction occurs with the adsorbed protein. After thorough washing with PBS buffer, the hollow fibers are cut into pieces of 2 mm length and placed in a polyethylene tube. 3-(p-hydroxyphenyl)propionic acid, which is a substrate for peroxidase, and aqueous hydrogen peroxide are added to this polyethylene tube, the enzymatic reaction is allowed to proceed for 1 hour, and the produced oxide is measured by fluorescence spectroscopy.
å®æœäŸïŒ
ïŒïŒïŒïŒïŒâããªã¯ããâïŒïŒïŒïŒïŒâããªãã«ãªããš
ã¿ã³âã¢ã»ãã³æ··å溶åªïŒã¢ã»ãã³ïŒïŒïŒïŒïœïœïŒ
ïŒïŒ
ïŒïŒïœïœã«ãç¡æ°Žã«ããã³é
žïŒïŒïŒïŒïŒãïœåã³ïŒâãž
ã¡ãã«ã¢ããããªãžã³ïŒïŒïŒïŒãïœãå ããåŠç液ã調
åããããã®åŠç液ã«åçã»ã«ããŒã¹äžç©ºç³žèïŒå
åŸïŒ
ïŒïŒÎŒïœãèåïŒïŒÎŒïœãé·ãçŽïŒïŒïœïœïŒãçŽïŒïŒïŒ
æ¬ãåçŽã«ïŒæéæã
äžäžã«åãããªãã浞挬ãããåŠ
çããäžç©ºç³žèãã¡ã¿ããŒã«äžã«äžæŒå€æµžæŒ¬ããåŸå®€æž©
ã§æžå§ä¹Ÿç¥ããåçã»ã«ããŒã¹äžç©ºç³žèãåŸããåŸãã
ãäžç©ºç³žèã®è£äœæ¶è²»çã®çµæã第ïŒè¡šã«ç€ºããExample 1 1.1.2-Trichloro-1,2,2-trifluoroethane-acetone mixed solvent (acetone 12.5 wt%) 2
0.047 g of caproic anhydride and 0.01 g of 4-dimethylaminopyridine were added to 50 ml to prepare a treatment liquid. This treatment solution was added to a regenerated cellulose hollow fiber membrane (inner diameter 2
00ÎŒm, film thickness 13ÎŒm, length approximately 20an) to approximately 600ÎŒm
The books were soaked vertically for 2 hours with occasional up and down movements. The treated hollow fiber membrane was immersed in methanol overnight and then dried under reduced pressure at room temperature to obtain a regenerated cellulose hollow fiber membrane. Table 1 shows the results of the complement consumption rate of the hollow fiber membranes obtained.
å®æœäŸïŒ
ç¡æ°Žã«ããã³é
žã®ä»£ããã«åçš®èèªæã«ã«ãã³é
žç¡æ°Žç©
ãçšãã以å€ã¯å®æœäŸïŒãšåæ§ãªæ¹æ³ã§ãšã¹ãã«åãã
åçš®åçã»ã«ããŒã¹äžç©ºç³žèãåŸãã第ïŒè¡šã«çšããè
èªæã«ã«ãã³é
žç¡æ°Žç©ãšãã®äœ¿çšéãåã³ãšã¹ãã«åã
ããåçã»ã«ããŒã¹äžç©ºç³žèã®è£äœæ¶è²»çã®çµæã瀺ã
ãExample 2 Esterification was carried out in the same manner as in Example 1 except that various aliphatic carboxylic acid anhydrides were used instead of caproic anhydride,
Various regenerated cellulose hollow fiber membranes were obtained. Table 1 shows the aliphatic carboxylic acid anhydrides used, their usage amounts, and the results of the complement consumption rate of the esterified regenerated cellulose hollow fiber membrane.
第ïŒè¡š
å®æœäŸïŒ
å®æœäŸïŒãïŒã®åçã»ã«ããŒã¹äžç©ºç³žèã«ã€ããŠïŒ¥ïŒ©ïŒ¡
æ³ã®æž¬å®ãå®æœãããçµæã第ïŒè¡šã«ç€ºããããªãã¡ã
æã¢ã«ããã³æäœãçšããå Žåã®èå
匷床ïŒïœãæã€ã
ãã°ãããªã³ã»ãžãŒæäœãçšããå Žåã®èå
匷床ïœã
æãã£ããªããŒã²ã³æäœãçšããå Žåã®èå
匷床ïœã
ããšãããšãããïœãïŒããïœã®å€åã³ïŒ©ãïœãïŒ
ããïœïŒ¯å€ããæªåŠçäžç©ºç³žèã§ã®å€ã§é€ããŠããã
ããïŒïŒ¡ïœïœïŒïŒ©ïœïŒ§ïŒåã³ïŒïŒ¡ïœïœïŒïŒŠïœïœïŒãšããŠ
瀺ããããã®ããã«ããŠåŸãããå€ã¯ãïŒïŒïŒïŒããã
倧ããããããã®äžç©ºç³žèã§ã¯ãæªåŠçäžç©ºç³žèããã
ã¢ã«ããã³ãéžæåžçããŠãããããããããããïŒä»¥
äžäœçœïŒç¬¬ïŒè¡š
å®æœäŸïŒ
ç¡æ°Žã«ããã³é
žïŒïŒïŒïŒïœãïŒâãžã¡ãã«ã¢ããããªãž
ã³ïŒïŒïŒïŒãïœåã³ïŒïŒïŒïŒïŒâããªã¯ããâïŒãïŒïŒ
ïŒâããªãã«ãªããšã¿ã³âã¢ã»ãã³æ··å溶åªïŒã¢ã»ãã³
ïŒïŒïŒïŒïœïœïŒ
ïŒïŒïŒïŒïœïœãå ãåŠç液ã調åãããTable 1 Example 3 EIA for regenerated cellulose hollow fiber membranes of Examples 1 and 2
The method measurements were carried out. The results are shown in Table 2. That is,
Fluorescence intensity 1a when using anti-albumin antibody, fluorescence intensity It when using anti-immunoglobulin G antibody,
Fluorescence intensity If when using anti-fibrinogen antibody,
Then, the value of I a / I i and I a /
The IfO value was divided by the value for the untreated hollow fiber membrane and expressed as (Alb/IgG) and (Alb/Fib), respectively. The value thus obtained is greater than 1.00, indicating that these hollow fiber membranes adsorb albumin more selectively than untreated hollow fiber membranes. (Margins below) Table 2 Example 4 0.44 g of caproic anhydride, 0.02 g of 4-dimethylaminopyridine, and 1.2 g of 1,1.2-trichloro-1°2.
A treatment solution was prepared by adding 700 ml of a 2-trifluoroethane-acetone mixed solvent (acetone 12.5 wt%).
ãã®åŠç液ã«åçã»ã«ããŒã¹äžç©ºç³žèïŒå
åŸïŒïŒïŒÎŒïœ
ãèåïŒïŒÎŒïœãé·ãïŒïŒïœïœïŒã®æïŒæ¬æ°çŽïŒïŒïŒïŒ
ïŒæ¬ïŒããæã
äžäžããªããïŒïŒåéåçŽã«æµžæŒ¬ãããThis treatment solution was added to a regenerated cellulose hollow fiber membrane (inner diameter 200 ÎŒm).
, film thickness 13 ÎŒm, length 30 cm) (approximately 7,00 pieces)
0) was immersed vertically for 30 minutes with occasional up and down movement.
åŠçåŸã®åçã»ã«ããŒã¹äžç©ºç³žèæãã¡ãã«ã¢ã«ã³ãŒã«
äžã«äžæŒå€æµžæŒ¬ããåŸã宀枩ã§æžå§ä¹Ÿç¥ããããšã«ãã£
ãŠãšã¹ãã«åãããäžç©ºç³žèæãåŸããThe treated regenerated cellulose hollow fiber membrane bundle was immersed in methyl alcohol for a day and night, and then dried under reduced pressure at room temperature to obtain an esterified hollow fiber membrane bundle.
第ïŒè¡šã«åŸãããäžç©ºç³žèã«ã€ããŠéææ§èœåã³è£äœæ¶
è²»çã®æž¬å®çµæã瀺ããTable 3 shows the measurement results of the dialysis performance and complement consumption rate of the hollow fiber membranes obtained.
次ã«ããã®äžç©ºç³žèãéæåšã«çµèŸŒã¿ãç¬ã«ããäœå€åŸª
ç°ãè¡ã£ããç¬ã¯äœéçŽïŒïŒïœïœã®ããŒã°ã«å€§ãçšãã
é éšã«é èšããã·ã£ã³ãããïŒïŒïŒïœïŒïŒïœïœïœã®è¡æµ
ããšã£ãŠéæåšè¡æ¶²åŽã«æµããããªãäœå€åŸªç°ã«å
ã ã£
ãŠãççé£å¡©æ°Žã§éæåšå
ãæŽæµããåŸããããªã³ïŒïŒ
ïŒïŒ¯ïŒ¯ïŒµïŒïŒ¬å«æã®ççé£å¡©æ°Žã§éæåšåã³è¡æ¶²åè·¯å
ãå
å¡«ãããã®åŸè¡æ¶²ãæµãããéæåšå
¥å£éšã§è¡æ¶²ã
æ¡åãçœè¡çæ°ã枬å®ãããéæçŽåã®çœè¡çæ°ãïŒïŒ
ïŒãšããæãéæåŸïŒïŒååã³ïŒïŒåã®äŸ¡ã¯ããããã
ïŒïŒåã³ïŒïŒã§ãã£ããNext, this hollow fiber membrane was installed in a dialyzer, and extracorporeal circulation was performed using a dog. The dog used was a peagle-sized dog weighing approximately 10 kg.
Blood flow at a rate of 100 ml/min was taken from a shunt created in the neck and flowed to the blood side of the dialyzer. Prior to extracorporeal circulation, after washing the inside of the dialyzer with physiological saline, heparin 6.
The inside of the dialyzer and blood circuit were filled with physiological saline containing 0 OOU/L, and then blood was allowed to flow. Blood was collected at the inlet of the dialyzer and the number of white blood cells was measured. White blood cell count just before dialysis to 10
When set to 0, the values 15 minutes and 30 minutes after dialysis were 78 and 82, respectively.
第ïŒè¡š
åèäŸ
第ïŒè¡šã«æªåŠçã®åçã»ã«ããŒã¹äžç©ºç³žèã«ã€ããŠéæ
æ§èœåã³è£äœæ¶è²»çã®æž¬å®çµæã瀺ããTable 3 Reference Example Table 3 shows the measurement results of dialysis performance and complement consumption rate for untreated regenerated cellulose hollow fiber membranes.
次ã«å®æœäŸïŒãšåæ§ã«ç¬ã«ããäœå€åŸªç°ãå®æœãããšã
ããéæçŽåã®çœè¡çæ°ãïŒïŒïŒãšããæãéæåŸïŒïŒ
ååã³ïŒïŒåã®äŸ¡ã¯ãããããïŒïŒåã³ïŒïŒã§ãã£ããNext, when extracorporeal circulation was performed using a dog in the same manner as in Example 4, it was found that when the white blood cell count immediately before dialysis was 100, the number of white blood cells after dialysis was 15.
The minute and 30 minute values were 13 and 45, respectively.
å®æœäŸïŒ
ïŒïŒïŒâã®æ ä»äžè§ãã©ã¹ã³ã«ãã«ããã³é
žç¡æ°Žç©ïŒïŒ
â ãïŒâãžã¡ãã«ã¢ããããªãžã³ïŒæãïŒïŒïŒïŒïŒâã
ããªã¯ããâïŒïŒïŒïŒïŒâããªãã«ãªããšã¿ã³âã¢ã»ã
ã³æ··å溶åªïŒã¢ã»ãã³ïŒïŒïŒïŒïœïœïŒ
ïŒïŒïŒïŒïœïœãå
ããåŠç液ã調åããã宀枩ã§ïŒæéæŸçœ®åŸãïŒãïŒã
ïœãïŒãïœé·ã«çŽ°æããåçã»ã«ããŒã¹äžç©ºç³žèïŒèå
ïŒïŒÎŒïœãå
åŸïŒïŒïŒÎŒïœïŒããïŒïŒïŒïœãåŠç液ã«æ
å
¥ããæ ãããŠãïŒïŒâã®æ°Žæº¶äžã§ïŒïŒåæ¯ãšããããExample 5 In a 200-mm Erlenmeyer flask with a stopper, 35 ml of caproic anhydride was added.
â , 4-dimethylaminopyridine 4 Akebono, 1.1.2-
100 ml of trichloro-1,2,2-trifluoroethane-acetone mixed solvent (acetone 12.5 wt%) was added to prepare a treatment liquid. After leaving it at room temperature for 2 hours, 2-3
4.5 g of a regenerated cellulose hollow fiber membrane (membrane thickness: 13 Όm, inner diameter: 200 Όm) cut into pieces of m/m length was added to the treatment solution, the membrane was stoppered, and the membrane was shaken in an aqueous solution at 30° C. for 30 minutes.
ãã®åŸäžç©ºç³žèããšãåºããã¡ãã«ã¢ã«ã³ãŒã«äžã«äžæŒ
å€æµžæŒ¬ããåŸãäžç©ºç³žèãæ¿Ÿå¥ãã宀枩ã§æžå§ä¹Ÿç¥ãã
ãåæ§ã«ããŠã調ååŸïŒïŒïŒïŒïŒïŒïŒïŒæé宀枩ã§æŸçœ®
ããåŠç液ã«ã€ããŠãå®æœããããããäžç©ºç³žèãåŸã
ãThereafter, the hollow fiber membrane was taken out and immersed in methyl alcohol for a day and night, then filtered off and dried under reduced pressure at room temperature. In the same manner, treatment solutions that had been left at room temperature for 4, 6, and 8.16 hours after preparation were also tested to obtain hollow fiber membranes, respectively.
è£äœæ¶è²»ç枬å®ã®çµæã第ïŒè¡šã«ç€ºãããïŒïŒæéã®æŸ
眮åŸãåŠç液ã®åå¿æ§ã¯å€ããããïŒæéãšåæ§ãªè£äœ
æ¶è²»çã瀺ããThe results of measuring the complement consumption rate are shown in Table 4, and the reactivity of the treatment solution did not change even after being left for 16 hours, showing the same complement consumption rate as after 2 hours.
第ïŒè¡š
åŠç液ã®æŸçœ®æéãããããè£äœæ¶è²»çïŒãããããã
ãããããïŒïŒïŒ
ïŒãããããããããããïŒïŒïŒ
ïŒãããããããããããïŒïŒïŒ
ïŒãããããããããããïŒïŒïŒ
ïŒïŒãããããããããããïŒïŒïŒ
ãçºæã®å¹æã
以äžã®èª¬æããæãããªããã«ãèèªæã«ã«ãã³é
žç¡æ°Ž
ç©ãåçã»ã«ããŒã¹èã«ãšã¹ãã«çµåãããããšã«ãã
ãåçã»ã«ããŒã¹èã®åªããéææ§èœãç¶æãããŸãŸã
è£äœæåã®æŽ»æ§åãæå¶ããçœè¡çã®äžéæ§æžå°ã軜æž
ãããããŸããã¢ã«ããã³ãéžæåžçããè¡æ¶²ã«å¯Ÿãã
é©åæ§ãæ¹è¯ããããTable 4: Leaving time of treatment solution Complement consumption rate 2
14% 4 14% 6 12% 8 13% 16 14% [Effects of the invention] As is clear from the above explanation, the superiority of the regenerated cellulose membrane can be improved by ester bonding the aliphatic carboxylic acid anhydride to the regenerated cellulose membrane. While maintaining the dialysis performance,
The activation of complement components is suppressed and the transient decrease in white blood cells is alleviated. In addition, albumin is selectively adsorbed and compatibility with blood is improved.
ç¹èš±åºé¡äººãæåæå·¥æ¥æ ªåŒäŒç€ŸPatent applicant: Asahi Kasei Industries, Ltd.
Claims (2)
é¢ã«èèªæã«ã«ãã³é žç¡æ°Žç©ããšã¹ãã«çµåãããããš
ãç¹åŸŽãšããæ¹è³ªãããåçã»ã«ããŒã¹è(1) A modified regenerated cellulose membrane characterized in that an aliphatic carboxylic acid anhydride is ester-bonded to at least the surface of the regenerated cellulose membrane that comes into contact with blood.
å¿åªäœã«æº¶è§£ãŸãã¯åæ£ããã溶液ã§åçã»ã«ããŒã¹è
ãåŠçããããšã«ãããèèªæã«ã«ãã³é žç¡æ°Žç©ãšèè¡š
é¢ã®æ°Žé žåºãšã®ãšã¹ãã«ååå¿ãè¡ãããšãç¹åŸŽãšãã
æ¹è³ªãããåçã»ã«ããŒã¹èã®è£œé æ¹æ³(2) By treating the regenerated cellulose membrane with a solution in which an aliphatic carboxylic acid anhydride and an esterification catalyst are dissolved or dispersed in a reaction medium, the esterification reaction between the aliphatic carboxylic anhydride and the hydroxyl groups on the membrane surface is carried out. A method for producing a modified regenerated cellulose membrane, characterized by carrying out
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62253724A JPH0199609A (en) | 1987-10-09 | 1987-10-09 | Reformed regenerated cellulose membrane and production thereof |
EP87116444A EP0266795B2 (en) | 1986-11-07 | 1987-11-06 | Improved regenerated cellulose membrane and process for preparation thereof |
DE3785147T DE3785147T2 (en) | 1986-11-07 | 1987-11-06 | Regenerated cellulose membrane and process for its manufacture. |
US07/488,511 US4999110A (en) | 1986-11-07 | 1990-02-28 | Regenerated cellulose membrane and processes for preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62253724A JPH0199609A (en) | 1987-10-09 | 1987-10-09 | Reformed regenerated cellulose membrane and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0199609A true JPH0199609A (en) | 1989-04-18 |
JPH0556174B2 JPH0556174B2 (en) | 1993-08-18 |
Family
ID=17255261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62253724A Granted JPH0199609A (en) | 1986-11-07 | 1987-10-09 | Reformed regenerated cellulose membrane and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0199609A (en) |
-
1987
- 1987-10-09 JP JP62253724A patent/JPH0199609A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH0556174B2 (en) | 1993-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4999110A (en) | Regenerated cellulose membrane and processes for preparation thereof | |
US5496637A (en) | High efficiency removal of low density lipoprotein-cholesterol from whole blood | |
US4800016A (en) | Extracorporeal blood de-heparinization system | |
US5187010A (en) | Membrane having high affinity for low density lipoprotein-cholesterol from whole blood | |
US5236644A (en) | Process of making membrane for removal of low density lipoprotein-cholesterol from whole blood | |
JPH04241873A (en) | Method and apparatus for removing heparin | |
JPH022848A (en) | Improved regenerated cellulose membrane and its production | |
JPH0199609A (en) | Reformed regenerated cellulose membrane and production thereof | |
JPS63236539A (en) | Immunoglobulin selective adsorbent | |
JPH0468009B2 (en) | ||
JPH0470047B2 (en) | ||
JP2002113097A (en) | Adsorbent and in vitro circulation column | |
Lin et al. | Preparation of modified polysulfone material decorated by sulfonated citric chitosan for haemodialysis and its haemocompatibility | |
JP4032465B2 (en) | Thrombogenic substance adsorbent and extracorporeal circulation column | |
JPH01297103A (en) | Improved regenerated cellulose film and its manufacture | |
JPH0536065B2 (en) | ||
JP2575487B2 (en) | Blood treatment material and blood purifier | |
US5073265A (en) | Methods of manufacturing nucleophilic material modified for improved biocompatibility | |
JP4196570B2 (en) | Hollow fiber membrane for plasma separation membrane or artificial kidney and module using the same | |
KR930002210B1 (en) | Blood Compatible Polymer Substituted with Sulfonated Polyethylene Oxide | |
JPS63238869A (en) | Blood compatible cellulosic dialytic membrane and its production | |
Huang et al. | Robust fabrication of poly (lactic acid) membrane with good hemocompatibility over heparinâmimetic grapheneâbased nanosheets | |
JP4830181B2 (en) | Hollow fiber membrane for lipid peroxide adsorption and module using the same | |
JP2002102692A (en) | Manufacturing method for lipoperoxide-adsorbing material | |
Irfan et al. | Polyurethane/N-3-(triethoxysilyl) propylamine grafted MCM41 membranes: hemocompatibility and dialysis evaluations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |